Klinik Dr. Hancken GmbH

Stade 10 trials 3 recruiting

10 Registered trials

3 Currently recruiting

Organisation

Klinik Dr. Hancken GmbH

Location

Stade, Germany

Identifier

ORG-100049574

Address

Harsefelder Strasse 8, 21680, Germany

Departments

Haematologie, Onkologie
Hämatologie und Onkologie
Hämatologie, Onkologie, Palliativmedizin
Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin
Klinik Dr. Hancken Stade
MVZ Hämatologie und Onkologie
Onkologie, Hämatologie
Onkologie/Hämotologie

Clinical trials at this site (10)

Search interface

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast… Ended

2023-505257-40-00 metastatic esophagogastric adenocarcinoma (Stage IV) 9 2024-04-17
Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization i… Ended

2023-504342-55-00 Cohort A: • Metastatic non-small cell lung carcinoma ( 10 2023-02-02
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15